Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Abstract

BACKGROUND: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell responses. Evaluation of vaccine efficacy was needed in a setting of ongoing SARS-CoV-2 transmission. METHODS: In this phase 2a-b trial in South Africa, we randomly assigned human immunodeficiency virus (HIV)-negative adults between the ages of 18 and 84 years or medically stable HIV-positive participants between the ages of 18 and 64 years in a 1:1 ratio to receive two doses of either the NVX-CoV2373 vaccine (5 μg of recombinant spike protein with 50 μg of Matrix-M1 adjuvant) or placebo. The primary end points were safety and vaccine efficacy against laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants without previous SARS-CoV-2 infection. RESULTS: Of 6324 participants who underwent screening, 4387 received at least one injection of vaccine or placebo. Approximately 30% of the participants were seropositive for SARS-CoV-2 at baseline. Among 2684 baseline seronegative participants (94% HIV-negative and 6% HIV-positive), predominantly mild-to-moderate Covid-19 developed in 15 participants in the vaccine group and in 29 in the placebo group (vaccine efficacy, 49.4%; 95% confidence interval [CI], 6.1 to 72.8). Vaccine efficacy among HIV-negative participants was 60.1% (95% CI, 19.9 to 80.1). Of 41 sequenced isolates, 38 (92.7%) were the B.1.351 variant. Post hoc vaccine efficacy against B.1.351 was 51.0% (95% CI, -0.6 to 76.2) among the HIV-negative participants. Preliminary local and systemic reactogenicity events were more common in the vaccine group; serious adverse events were rare in both groups. CONCLUSIONS: The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT04533399.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 25

1. 1.

   World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessd December 28, 2020.

   Not in our library

2. 2.

   World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed December 28, 2020.

   Not in our library

3. 3.

   Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020;19:667–8.

   Not in our library10.1038/d41573-020-00151-8

4. 4.

   Baden FP, Thomas SJ, Kitchin N,; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.

   Not in our library10.1056/nejmoa2034577

5. 5.

   Polack FP, Thomas SJ, Kitchin N,; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.

   Not in our library10.1056/nejmoa2034577

6. 6.

   Logunov DY, Dolzhikova IV, Shcheblyakov DV, Safety and efficacy of an rAd26 and rAd5 vector-based heter8ologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021..

   Not in our library10.1016/s0140-6736(21)00234-8

7. 7.
   Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021

   Corrected
8. 8.

   US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Announcement. Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement. Accessed March 1, 2021.

   Not in our library

9. 9.
   Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate · 2020

   No notice
10. 10.
    SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice · 2021

    No notice
11. 11.

    Keech C, Albert G, Cho I, Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020:383:2320–32.

    Not in our library10.1056/nejmoa2026920

12. 12.

    Cele S, S, Gazy I, Jackson L, Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medrxiv 2021...

    Not in our library10.1101/2021.01.26.21250224

13. 13.

    Greaney AJ, Loes AN, Crawford KHD, Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. biorxiv 2021..

    Not in our library10.1101/2020.12.31.425021

14. 14.

    Sabino EC, Buss LF, Carvalho MPS, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 2021;397:452–455.

    Not in our library10.1016/s0140-6736(21)00183-5

15. 15.

    Tegally H, Wilkinson E, Giovanetti M, Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020..

    Not in our library10.1101/2020.12.21.20248640

16. 16.

    Volz E, Mishra S, Chand M, Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv 2021. https://doi.org/10.1101.2020.12.30.20249034.

    Not in our library

17. 17.

    Wang P, Liu L, Iketani S, Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv 2021..

    Not in our library10.1101/2021.01.25.428137

18. 18.

    Wang Z, Schmidt F, Weisblum Y, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature2021.. Online ahead of print.

    Not in our library10.1038/s41586-021-03324-6

19. 19.

    Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern?. Lancet Respir Med 2021..

    Not in our library10.1016/s2213-2600(21)00075-8

20. 20.

    Hsiao M. SARS-CoV-2 seroprevalence in the Cape Town metropolitan sub-districts after the peak of infections. In: Service DoNHL, ed. 2020:1–9.

    Not in our library

21. 21.
    Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding · 2020

    No notice
22. 22.

    Wibmer CK, Ayres F, Hermanus T, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv 2021..

    Not in our library10.1101/2021.01.18.427166

23. 23.

    Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. Novavax, Inc. January 28, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Accessed February 18, 2021.

    Not in our library

24. 24.

    Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. January 29, 2021. https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial. Accessed February 18, 2021.

    Not in our library

25. 25.

    Madhi SA, Baillie V, Cutland CL. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. medRxiv 2021. https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1.

    Not in our library10.1056/nejmoa2102214

Cited by papers we hold 22

• COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron) · 2022
  Not checked
• Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy · 2022
  Not checked
• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
  No notice
• A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
  No notice
• Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials · 2022
  No notice
• Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases · 2022
  No notice
• Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
  Not checked
• Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis · 2021
  No notice
• Self-reported mask-related worrying reduces relative avoidance bias toward unmasked faces in individuals with low Covid19 anxiety syndrome · 2021
  Not checked
• SARS-CoV-2-specific T cells in infection and vaccination · 2021
  No notice
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies · 2021
  No notice
• Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis · 2021
  No notice
• The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern · 2021
  No notice
• Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study · 2021
  No notice
• SARS-CoV-2 one year on: evidence for ongoing viral adaptation · 2021
  No notice

and 2 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.